Loading
A year of atezolizumab plus bevacizumab after surgery or ablation for high-risk liver cancer initially reduced recurrences, but the benefit disappeared with longer follow-up, so there is still no proven adjuvant therapy.
Phase 3 trial of 668 patients with hepatocellular carcinoma at high risk of recurrence after resection or ablation randomised to 12 months of atezolizumab plus bevacizumab or active surveillance.
At the first interim analysis recurrence-free survival favoured treatment (hazard ratio 0.72), but the updated analysis showed the curves converging (hazard ratio 0.90) with no overall survival benefit; bleeding and immune-related events occurred in the treatment arm.
Adjuvant immunotherapy is not standard after curative treatment of hepatocellular carcinoma; surveillance, antiviral therapy and risk factor control remain the approach.
Shares Atezolizumab, Bevacizumab.
Shares Atezolizumab, Bevacizumab.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Bevacizumab.
Shares Atezolizumab, Bevacizumab.
Shares IMbrave050, Atezolizumab.
Shares Atezolizumab, Bevacizumab.
Shares The Lancet, Bevacizumab.
Shares Atezolizumab, Bevacizumab.